Revolutionizing the Standard of Care for MDD Treatment – Circular Genomics
Circular Genomics is a pioneering precision neurology/psychiatry medicine biotech company, focused on revolutionizing the standard of care in mental health and neurology. We develop technologies based on circular RNAs which are known to play a role in brain development, cognition, behavior, mood, and more. Our flagship clinical test is MindLight Antidepressant Response Test™, a blood test that provides precision information empowering physicians to direct their major depressive disorder (MDD) patients to the right medication at diagnosis, avoiding the educated guessing that is the current standard of care. MindLight analyzes circular RNA in patients with major depressive disorder (MDD), stratifying patients by their likelihood to respond to SSRIs.